This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The direct costs were those of the drugs; monitoring; patient management whilst on antiviral treatment; liver transplantation; and the health states of relapse, chronic hepatitis C, cirrhosis, and hepatocellular carcinoma. The drug unit costs were from the 2009 British National Formulary. The costs of monitoring and management were from a published economic evaluation. The health state costs were from an observational study conducted alongside a trial. The liver transplantation costs were from a UK study. All costs were reported in UK £, at 2007 to 2008 prices. Future costs were discounted at an annual rate of 3.5%.
Analysis of uncertainty:
One-way sensitivity analyses were undertaken to assess the areas that were most uncertain and had the most impact on the results. A probabilistic sensitivity analysis was conducted to assess parameter uncertainty, with distributions assigned to the main estimates. The details of the probabilistic analysis were reported in Hartwell, et al. (2011, see Other Publications of Related Interest).
Results
Depending on the source trial, for patients with genotype one, the QALYs ranged from 15.68 to 19.74 for standard treatment, and from 15.54 to 20.03 for short treatment. The costs ranged from £14,206 to £26,169 for standard treatment, and from £8,994 to £17,173 for short treatment. Compared with standard pegylated interferon-alpha-2a and ribavirin for 48 weeks, short 24-week treatment had an incremental cost per QALY gained of £34,510 or £64,880. Compared with standard pegylated interferon-alpha-2b and ribavirin, short treatment was dominant, as it was cheaper and more effective.
For genotypes two or three, the QALYs were 15.31 or 15.64 for standard treatment, and 15.54 or 15.72 for short treatment. The costs were £7,834 or £10,089 for standard treatment, and £5,728 or £6,943 for short treatment. Compared with standard pegylated interferon-alpha-2a and ribavirin for 24 weeks, short 16-week treatment was dominant, using either set of data.
The probabilistic sensitivity analysis showed that for genotype one, short treatment with pegylated interferon-alpha-2a was cost-effective in at least 83% of simulations, at a willingness-to-pay threshold of £20,000 and 59% of simulations at a threshold of £30,000 per QALY gained. For genotypes two or three, short treatment was cost-effective in 100% of simulations.
